Treatment

The main medication to treat hemophilia is concentrated FVIII product, called clotting factor. Recombinant factor products, which are are developed in a lab through the use of DNA technology, preclude the use of human-derived pools of donor-sourced plasma. And while plasma-derived FVIII products are still available, approximately 75% of the hemophilia community takes a recombinant FVIII product.